GLS and non-small cell lung carcinoma: Several selective inhibitors of glutaminase (GLS), the rate-limiting enzyme responsible for the deamination of glutamine to glutamate, such as BPTES or CB-839, have now been tested in several pre-clinical cancer models including NSCLC, breast, pancreatic, renal, leukemia and lymphoma [5].